Vanguard Global Advisers
GALT icon

Vanguard Global Advisers’s Galectin Therapeutics GALT Stock Holding History

Vanguard Global Advisers’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.8K Hold
18,065
– – ﹤0.01% 2854
2026
Q1 		$50.4K Buy
+18,065
New +$55K ﹤0.01% 3020

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's GALT Position: Q2 2026 in Review

Vanguard Global Advisers held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 18,065 shares worth $83.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

Vanguard Global Advisers first reported a position in GALT in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Vanguard Global Advisers held 18,065 shares of Galectin Therapeutics worth $83.8K as of Q2 2026.
  • Vanguard Global Advisers left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2854 holding.
  • Vanguard Global Advisers first reported a position in Galectin Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.